Rezolute, Inc.

Rezolute, Inc. is a late-stage rare disease biopharmaceutical company focused on developing therapies for refractory and debilitating hypoglycemia associated with forms of hyperinsulinism. The company's principal clinical asset is ersodetug, an intravenously administered human monoclonal antibody designed to down-modulate insulin receptor activity and normalize blood glucose levels. Its pipeline targets conditions such as congenital hyperinsulinism in pediatric patients and tumor hyperinsulinism caused by neuroendocrine islet cell tumors and non-islet cell tumors. Potential end users and target recipients include pediatric individuals suffering from congenital hyperinsulinism, as well as hospitalized or adult patients with inoperable or metastatic tumors experiencing severe hypoglycemia.

The company operates in the United States and has conducted multinational clinical studies for its therapeutic programs. Rezolute maintains an executive office and headquarters located in Redwood City, California, and employed 58 full-time staff members based entirely in the United States as of June 30, 2026.

Summary of the business section of Rezolute's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

“As of June 30, 2026, we had 58 full-time employees, of which 40 employees were engaged in research and development and 18 employees were engaged in general and administrative functions.”